Guhl G, González-de Arriba A, Daudén E. Efectos cutáneos de los inhibidores del receptor del factor de crecimiento epidérmico.
ACTAS DERMO-SIFILIOGRAFICAS 2006;
97:296-310. [PMID:
16956561 DOI:
10.1016/s0001-7310(06)73407-x]
[Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Epidermal growth factor receptor (EGFR) inhibitors are a new group of drugs used in the treatment of several malignancies. Three molecules are approved at the moment: gefitinib and erlotinib for the treatment of non-small-cell lung cancer, and cetuximab for colorectal cancer. These drugs originate cutaneous side effects with a high frequency: acneiform rashes, paronychia and generalized xerodermia. In this paper we review these common side effects and how to manage them.
Collapse